批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2012/09/27 |
ORIG-1(原始申请) |
Approval |
Type 1 - New Molecular Entity |
PRIORITY
;Orphan
|
|
|
>>>补充申请<<<
审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2025/02/25 |
SUPPL-16(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
2020/12/10 |
SUPPL-14(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
2020/09/24 |
SUPPL-12(补充) |
Approval |
Labeling-Container/Carton Labels |
STANDARD
;Orphan
|
|
|
2020/07/21 |
SUPPL-13(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
2020/02/13 |
SUPPL-11(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
2019/07/31 |
SUPPL-10(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
2018/06/14 |
SUPPL-8(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
;Orphan
|
|
|
2017/04/27 |
SUPPL-7(补充) |
Approval |
Efficacy-New Indication |
PRIORITY
;Orphan
|
|
|
2016/08/26 |
SUPPL-6(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
2016/06/07 |
SUPPL-5(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
2015/04/13 |
SUPPL-4(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
2014/11/10 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2013/09/13 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2013/05/29 |
SUPPL-1(补充) |
Approval |
Labeling-Package Insert |
STANDARD
;Orphan
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
与本品治疗等效的药品
>>>活性成分:REGORAFENIB; 剂型/给药途径:TABLET;ORAL; 规格:40MG; 治疗等效代码:AB<<<
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
203085 |
001 |
NDA |
STIVARGA |
REGORAFENIB |
TABLET;ORAL |
40MG |
Prescription |
Yes |
Yes |
AB |
2012/09/27
|
BAYER HLTHCARE |
209728 |
001 |
ANDA |
REGORAFENIB |
REGORAFENIB |
TABLET;ORAL |
40MG |
Prescription |
No |
No |
AB |
2025/01/13
|
ACTAVIS LABS FL |